A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (14) , 2093-2095
- https://doi.org/10.1016/0959-8049(94)00297-i
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—Dacarbazine and fotemustine—in patients with melanomaEuropean Journal Of Cancer, 1993
- Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanomaBritish Journal of Cancer, 1993
- Fotemustine plus dacarbazine for malignant melanomaEuropean Journal Of Cancer, 1992
- IntroductionPublished by Springer Nature ,1992
- Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanomaAnnals of Oncology, 1991
- Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesCancer, 1990